Arrowstreet Capital
FATE icon

Arrowstreet Capital’s Fate Therapeutics FATE Stock Holding History

Arrowstreet Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.5K Buy
+30,176
New +$55.8K ﹤0.01% 1877
2025
Q1 		– Sell
-25,580
Closed -$42.2K – 1867
2024
Q4 		$42.2K Sell
25,580
-6,518
-20% -$16.4K ﹤0.01% 1700
2024
Q3 		$112K Buy
+32,098
New +$125K ﹤0.01% 1679
2021
Q4 		– Sell
-25,100
Closed -$1.49M – 1522
2021
Q3 		$1.49M Buy
25,100
+21,300
+561% +$1.67M ﹤0.01% 1203
2021
Q2 		$330K Buy
+3,800
New +$306K ﹤0.01% 1732
2021
Q1 		– Sell
-69,636
Closed -$6.33M – 2323
2020
Q4 		$6.33M Buy
69,636
+35,477
+104% +$2.2M 0.01% 1101
2020
Q3 		$1.36M Buy
+34,159
New +$1.19M ﹤0.01% 1710
2020
Q1 		– Sell
-31,900
Closed -$624K – 1942
2019
Q4 		$624K Buy
+31,900
New +$507K ﹤0.01% 1447
2019
Q2 		– Sell
-19,300
Closed -$339K – 1480
2019
Q1 		$339K Buy
19,300
+8,530
+79% +$135K ﹤0.01% 1564
2018
Q4 		$138K Buy
+10,770
New +$150K ﹤0.01% 1283

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arrowstreet Capital's FATE Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in Fate Therapeutics (FATE) in Q2 2026: 30,176 shares worth $81.5K. The stake represents ﹤0.01% of the portfolio and ranks #1877 among its holdings. This is a return to the name: Arrowstreet Capital previously reported a position in FATE as recently as Q4 2024.

Arrowstreet Capital first reported a position in FATE in Q4 2018 and has held it in 10 quarters since. The position peaked at $6.33M in Q4 2020. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Arrowstreet Capital held 30,176 shares of Fate Therapeutics worth $81.5K as of Q2 2026.
  • Fate Therapeutics was a new Arrowstreet Capital position in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1877 holding.
  • Arrowstreet Capital first reported a position in Fate Therapeutics in Q4 2018 and has held it in 10 quarters since.
  • Arrowstreet Capital's Fate Therapeutics position peaked at $6.33M in Q4 2020.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.